152 related articles for article (PubMed ID: 31917403)
1. Sildenafil triggers tumor lethality through altered expression of HSP90 and degradation of PKD2.
Chen L; Liu Y; Becher A; Diepold K; Schmid E; Fehn A; Brunner C; Rouhi A; Chiosis G; Cronauer M; Seufferlein T; Azoitei N
Carcinogenesis; 2020 Oct; 41(10):1421-1431. PubMed ID: 31917403
[TBL] [Abstract][Full Text] [Related]
2. Physical plasma-triggered ROS induces tumor cell death upon cleavage of HSP90 chaperone.
Bekeschus S; Lippert M; Diepold K; Chiosis G; Seufferlein T; Azoitei N
Sci Rep; 2019 Mar; 9(1):4112. PubMed ID: 30858416
[TBL] [Abstract][Full Text] [Related]
3. Hsp90 inhibition by PU-H71 induces apoptosis through endoplasmic reticulum stress and mitochondrial pathway in cancer cells and overcomes the resistance conferred by Bcl-2.
Gallerne C; Prola A; Lemaire C
Biochim Biophys Acta; 2013 Jun; 1833(6):1356-66. PubMed ID: 23485394
[TBL] [Abstract][Full Text] [Related]
4. PDE5 inhibitors enhance the lethality of [pemetrexed + sorafenib].
Booth L; Roberts JL; Poklepovic A; Dent P
Oncotarget; 2017 Feb; 8(8):13464-13475. PubMed ID: 28088782
[TBL] [Abstract][Full Text] [Related]
5. The Rationale for Repurposing Sildenafil for Lung Cancer Treatment.
Keats T; Rosengren RJ; Ashton JC
Anticancer Agents Med Chem; 2018; 18(3):367-374. PubMed ID: 29110626
[TBL] [Abstract][Full Text] [Related]
6. Over-expression of PDE5 in Oral Squamous Cell Carcinoma - Effect of Sildenafil Citrate.
Iwasaki T; Onda T; Honda H; Hayashi K; Shibahara T; Nomura T; Takano M
Anticancer Res; 2021 May; 41(5):2297-2306. PubMed ID: 33952455
[TBL] [Abstract][Full Text] [Related]
7. PDE5 inhibitor sildenafil attenuates cardiac microRNA 214 upregulation and pro-apoptotic signaling after chronic alcohol ingestion in mice.
Samidurai A; Xi L; Salloum FN; Das A; Kukreja RC
Mol Cell Biochem; 2020 Aug; 471(1-2):189-201. PubMed ID: 32535704
[TBL] [Abstract][Full Text] [Related]
8. PDE5 expression in human thyroid tumors and effects of PDE5 inhibitors on growth and migration of cancer cells.
Sponziello M; Verrienti A; Rosignolo F; De Rose RF; Pecce V; Maggisano V; Durante C; Bulotta S; Damante G; Giacomelli L; Di Gioia CR; Filetti S; Russo D; Celano M
Endocrine; 2015 Nov; 50(2):434-41. PubMed ID: 25837309
[TBL] [Abstract][Full Text] [Related]
9. Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells.
Rouhi A; Miller C; Grasedieck S; Reinhart S; Stolze B; Döhner H; Kuchenbauer F; Bullinger L; Fröhling S; Scholl C
Oncotarget; 2017 Jan; 8(5):7678-7690. PubMed ID: 28032595
[TBL] [Abstract][Full Text] [Related]
10. Phosphodiesterase 5 inhibitor sildenafil potentiates the antitumor activity of cisplatin by ROS-mediated apoptosis: a role of deregulated glucose metabolism.
Rawat SG; Tiwari RK; Jaiswara PK; Gupta VK; Sonker P; Vishvakarma NK; Kumar S; Pathak C; Gautam V; Kumar A
Apoptosis; 2022 Aug; 27(7-8):606-618. PubMed ID: 35725975
[TBL] [Abstract][Full Text] [Related]
11. PDE5 inhibitors enhance the lethality of pemetrexed through inhibition of multiple chaperone proteins and via the actions of cyclic GMP and nitric oxide.
Booth L; Roberts JL; Poklepovic A; Gordon S; Dent P
Oncotarget; 2017 Jan; 8(1):1449-1468. PubMed ID: 27903966
[TBL] [Abstract][Full Text] [Related]
12. Calcilytics enhance sildenafil-induced antiproliferation in idiopathic pulmonary arterial hypertension.
Yamamura A; Yagi S; Ohara N; Tsukamoto K
Eur J Pharmacol; 2016 Aug; 784():15-21. PubMed ID: 27164419
[TBL] [Abstract][Full Text] [Related]
13. Phosphodiesterase 5 Associates With β2 Adrenergic Receptor to Modulate Cardiac Function in Type 2 Diabetic Hearts.
West TM; Wang Q; Deng B; Zhang Y; Barbagallo F; Reddy GR; Chen D; Phan KS; Xu B; Isidori A; Xiang YK
J Am Heart Assoc; 2019 Aug; 8(15):e012273. PubMed ID: 31311394
[TBL] [Abstract][Full Text] [Related]
14. PDE5 inhibitors - pharmacology and clinical applications 20 years after sildenafil discovery.
Andersson KE
Br J Pharmacol; 2018 Jul; 175(13):2554-2565. PubMed ID: 29667180
[TBL] [Abstract][Full Text] [Related]
15. Neratinib augments the lethality of [regorafenib + sildenafil].
Booth L; Roberts JL; Rais R; Cutler RE; Diala I; Lalani AS; Hancock JF; Poklepovic A; Dent P
J Cell Physiol; 2019 Apr; 234(4):4874-4887. PubMed ID: 30203445
[TBL] [Abstract][Full Text] [Related]
16. Differentiation of human neuroblastoma cell line IMR-32 by sildenafil and its newly discovered analogue IS00384.
Dar MI; Jan S; Reddy GL; Wani R; Syed M; Dar MJ; Sawant SD; Vishwakarma RA; Syed SH
Cell Signal; 2020 Jan; 65():109425. PubMed ID: 31689507
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma.
Giulino-Roth L; van Besien HJ; Dalton T; Totonchy JE; Rodina A; Taldone T; Bolaender A; Erdjument-Bromage H; Sadek J; Chadburn A; Barth MJ; Dela Cruz FS; Rainey A; Kung AL; Chiosis G; Cesarman E
Mol Cancer Ther; 2017 Sep; 16(9):1779-1790. PubMed ID: 28619753
[TBL] [Abstract][Full Text] [Related]
18. Melanoma, Viagra, and PDE5 Inhibitors: Proliferation and Metastasis.
Houslay MD
Trends Cancer; 2016 Apr; 2(4):163-165. PubMed ID: 28741569
[TBL] [Abstract][Full Text] [Related]
19. Novel effect of sildenafil on hair growth.
Choi HI; Kang BM; Jang J; Hwang ST; Kwon O
Biochem Biophys Res Commun; 2018 Nov; 505(3):685-691. PubMed ID: 30292404
[TBL] [Abstract][Full Text] [Related]
20. Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy.
Ying W; Du Z; Sun L; Foley KP; Proia DA; Blackman RK; Zhou D; Inoue T; Tatsuta N; Sang J; Ye S; Acquaviva J; Ogawa LS; Wada Y; Barsoum J; Koya K
Mol Cancer Ther; 2012 Feb; 11(2):475-84. PubMed ID: 22144665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
